HER2 status by standardized immunohistochemistry and silver-enhanced In Situ hybridization in Korean breast cancer

Journal of Breast Cancer

Volumn 15, Issue 4, 2012, Pages 381-387

  Bae, Young Kyung ^a   Gong, Gyungyub ^b   Kang, Jun ^c   Lee, Ahwon ^d   Cho, Eun Yoon ^e   Lee, Ji Shin ^f   Suh, Kwang Sun ^g   Lee, Dong Wha ^h   Jung, Woo Hee ⁱ  

^a Yeungnam University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d The Catholic University of Korea College of Medicine   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f Chonnam National University Medical School   (South Korea)

^g Chungnam National University College of Medicine   (South Korea)

^h Soonchunhyang University College of Medicine   (South Korea)

ⁱ Yonsei University College of Medicine   (South Korea)

Author keywords

Breast neoplasms; HER2 gene; Immunohistochemistry; Silverenhanced in situ hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; SILVER;

ADULT; AGED; ARTICLE; BREAST CANCER; CHROMOSOME 17; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OBSERVER VARIATION; PROTEIN EXPRESSION; SILVER STAINING; TISSUE MICROARRAY;

EID: 84872351672     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2012.15.4.381     Document Type: Article

References (16)

1. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
3. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14: 320-68.
4. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287-312.
5. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;27:1323-33.
6. Dietel M, Ellis IO, Höfler H, Kreipe H, Moch H, Dankof A, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 2007;451:19-25.
7. Kang J, Kwon GY, Lee YH, Gong G. Comparison of silver-enhanced in situ hybridization and fluorescence in situ hybridization for HER2 gene status in breast carcinomas. J Breast Cancer 2009;12:235-40.
8. Sung WJ, Park SJ, Gu MJ, Bae YK. Automated silver-enhanced in situ hybridization for evaluation of HER2 gene status in breast carcinoma: comparison with fluorescence in situ hybridization and immunohistochemistry. Korean J Pathol 2010;44:28-34.
9. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Realworld performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-4.
10. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-7.
11. Elston CW, Ellis IO., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
12. van der Vegt B, de Bock GH, Bart J, Zwartjes NG, Wesseling J. Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. Mod Pathol 2009;22:879-86.
13. De P, Smith BR, Leyland-Jones B. Human epidermal growth factor receptor 2 testing: where are we? J Clin Oncol 2010;28:4289-92.
14. Park K, Han S, Kim JY, Kim HJ, Kwon JE, Gwak G. Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer. J Breast Cancer 2011;14:276-82.
15. Park S, Park HS, Koo JS, Yang WI, Kim SI, Park BW. Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization. Cancer 2012;118:914-23.
16. Bilous M, Farshid G. Assessment of human epidermal growth factor receptor 2 (HER2) amplification by in situ hybridization (ISH): findings from a nationwide program in Australia. 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium. 2009. Abstract #5100.